

# EuroValve

March 27 - 28, 2015


Improving risk stratification in asymptomatic severe aortic stenosis


## Myocardial fibrosis with MRI

Victoria Delgado, MD, PhD

Leiden University Medical Center

The Netherlands





# EuroValve


March 27 - 28, 2015

## Faculty disclosure


*Victoria Delgado*

*I disclose the following financial relationships:*


**Paid speaker** for Abbott Vascular




[www.eurovalvecongress.com](http://www.eurovalvecongress.com)





# EuroValve



- Poor correlation between severity of aortic stenosis and symptom onset
- Management of asymptomatic severe AoS patients challenging



# EuroValve




Hypertrophy




Heart failure




Cardiomyocyte death  
Replacement fibrosis



## Magnetic resonance imaging to detect myocardial fibrosis



## Biomarkers to detect cardiomyocyte death



# EuroValve




**N=122, 71 [65–77] years, 67% males**

**aortic valve area  $1.0 \pm 0.4 \text{ cm}^2$**

N=13 healthy volunteers



- Correlation between high-sensitivity TnI and LV hypertrophy
- Characterization with LGE and T1 mapping MRI techniques:
  - replacement fibrosis
  - interstitial fibrosis




# EuroValve



More advance grade of myocardial fibrosis  
Increased high-sensitivity TnI levels











# EuroValve




Peak aortic velocity 4.8m/s  
LV mass index 114 g/m<sup>2</sup>  
High-sensitivity TnI 11.9ng/L




Peak aortic velocity 5.1m/s  
LV mass index 81 g/m<sup>2</sup>  
High-sensitivity TnI 2.5ng/L








## Prognostic implications?







## Prognostic implications?

**N=154, mean age 74±9 years, 62% male**


**AVA 0.71±0.17 cm<sup>2</sup>, 29% CAD**



	0	1	2	3	4	5
no LGE	110	92	66	48	12	5
LGE	44	33	30	21	9	8




	0	1	2	3	4	5
no LGE	110	92	66	48	12	5
LGE	44	33	30	21	9	8




## Fibrosis regression after AVR?


**No Fibrosis**




**Mild Fibrosis**



**Severe Fibrosis**









# EuroValve



N= 58  
Symptomatic severe AS





# EuroValve



## No Fibrosis

Baseline      9 Months

NYHA  
Class I:

I  
n=0

I  
n=14

NYHA  
Class II:

II  
n=5

II  
n=8

NYHA  
Class III:

III  
n=17

III  
n=0

NYHA  
Class IV:

IV  
n=0

IV  
n=0

## Mild Fibrosis

Baseline      9 Months

I  
n=0

I  
n=8

II  
n=2

II  
n=3

III  
n=12

III  
n=4

IV  
n=1

IV  
n=0

## Severe Fibrosis

Baseline      9 Months

I  
n=0

I  
n=0

II  
n=0

II  
n=0


III  
n=14

III  
n=14


IV  
n=7


IV  
n=3

died  
n=4



## T1 mapping MRI






# EuroValve



Pre-contrast




Basal

Mid Cavity


Apical

Post-contrast




$$\lambda = \Delta R1_{\text{myocardium}} / \Delta R1_{\text{blood pool}}, \text{ where } R1 = 1/T1$$


$$ECV = (1 - \text{hematocrit}) \times \lambda$$




# EuroValve








# EuroValve





## Conclusions

- In asymptomatic aortic stenosis patients, detection of myocardial fibrosis may help to:
  - Identify patients at risk of developing heart failure
  - Refine the decision making
- Which technique to use?
  - Replacement fibrosis (may be late)
  - Diffuse fibrosis (ideal, but still validation studies)